Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Septerna, Inc.

Contributing Author

Recent Articles by Septerna, Inc.

Aug-10
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results SEPN SEPN +22.93% GlobeNewswire
May-11
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results SEPN SEPN +5.39% GlobeNewswire
May-05
Septerna to Present at Bank of America Securities Health Care Conference SEPN GlobeNewswire
Apr-13
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism SEPN GlobeNewswire
Mar-09
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results SEPN GlobeNewswire
Mar-01
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy SEPN GlobeNewswire
Feb-24
Septerna to Present at TD Cowen 46th Annual Health Care Conference SEPN +10.21% GlobeNewswire
Feb-10
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SEPN GlobeNewswire
Feb-10
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting SEPN GlobeNewswire
Jan-08
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer SEPN GlobeNewswire
Dec-17
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference SEPN GlobeNewswire
Nov-25
Septerna to Participate in 8th Annual Evercore Healthcare Conference SEPN GlobeNewswire
Nov-10
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results SEPN GlobeNewswire
Nov-03
Septerna to Participate in Upcoming Investor Conferences SEPN GlobeNewswire
Sep-29
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors SEPN GlobeNewswire
Aug-27
Septerna to Participate in Upcoming Investor Conferences SEPN GlobeNewswire
Aug-21
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases SEPN +5.50% GlobeNewswire
Aug-11
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results SEPN GlobeNewswire
May-29
Septerna to Present at Jefferies Global Healthcare Conference SEPN GlobeNewswire
May-15
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results SEPN GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)